Top-Rated StocksTop-RatedNASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $21.04 -0.12 (-0.57%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sutro Biopharma Stock (NASDAQ:STRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$20.84▼$21.8650-Day Range$20.48▼$33.3552-Week Range$7.15▼$43.85Volume194,680 shsAverage Volume296,940 shsMarket Capitalization$348.84 millionP/E RatioN/ADividend YieldN/APrice Target$47.30Consensus RatingBuy Company Overview Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas. With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.AI Generated. May Contain Errors. Read More Sutro Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 275th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSutro Biopharma has a consensus price target of $47.30, representing about 124.8% upside from its current price of $21.04.Amount of Analyst CoverageSutro Biopharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($8.41) to ($6.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Sutro Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.72% of the float of Sutro Biopharma has been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 6.35.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentSutro Biopharma has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sutro Biopharma this week, compared to 3 articles on an average week.Search Interest1 people have searched for STRO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders1.80% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Stock News HeadlinesSutro Biopharma Q3 EPS Forecast Decreased by HC WainwrightAugust 16, 2026 | americanbankingnews.comWedbush Reiterates Outperform Rating for Sutro Biopharma (NASDAQ:STRO)August 15, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 23 at 1:00 AM | InvestorPlace (Ad)Citizens Jmp Issues Pessimistic Forecast for Sutro Biopharma (NASDAQ:STRO) Stock PriceAugust 15, 2026 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Buy" from BrokeragesAugust 15, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)August 14, 2026 | theglobeandmail.comSTRO stock plummets 15% — what drove the selloff?August 12, 2026 | msn.comWhy is Sutro Biopharma Stock Falling On Wednesday?August 12, 2026 | benzinga.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $11.57 at the start of the year. Since then, STRO shares have increased by 81.8% and is now trading at $21.04. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.19) by $0.14. The business earned $9.84 million during the quarter, compared to analysts' expectations of $11.96 million. When did Sutro Biopharma's stock split? Shares of Sutro Biopharma reverse split before market open on Wednesday, December 3rd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $85 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,667,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's top institutional shareholders include Merck & Co. Inc. (1.64%), Seven Fleet Capital Management LP (0.96%), Bank of New York Mellon Corp (0.25%) and Wellington Management Group LLP (0.07%). Insiders that own company stock include Jane Chung, Hans-Peter Gerber, David Pauling, Connie Matsui, Gregory K Chow, Nicki Vasquez and Brunilda Shtylla. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings8/12/2026Today8/23/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 11 days, STRO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STRO CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year Founded2003Price Target and Rating Average Price Target for Sutro Biopharma$47.30 High Price Target$60.00 Low Price Target$27.00 Potential Upside/Downside+124.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($11.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$191.09 million Net Margins-395.25% Pretax Margin-395.46% Return on EquityN/A Return on Assets-88.12% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$102.48 million Price / Sales3.40 Cash FlowN/A Price / Cash FlowN/A Book Value($6.23) per share Price / Book-3.38Miscellaneous Outstanding Shares16,580,000Free Float16,283,000Market Cap$348.84 million OptionableOptionable Beta1.55 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:STRO) was last updated on 8/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
